BioDelivery Sciences International (NASDAQ:BDSI) was downgraded by research analysts at BidaskClub from a “hold” rating to a “sell” rating in a report issued on Saturday, BidAskClub reports.
BDSI has been the subject of a number of other research reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $8.00 price target on shares of BioDelivery Sciences International in a report on Monday, May 25th. Northland Securities started coverage on shares of BioDelivery Sciences International in a report on Wednesday, April 22nd. They issued an “outperform” rating and a $9.00 price target for the company. Roth Capital reaffirmed a “buy” rating and issued a $9.25 price target on shares of BioDelivery Sciences International in a report on Monday, May 25th. Finally, Piper Sandler reaffirmed a “market perform” rating and issued a $9.00 price target on shares of BioDelivery Sciences International in a report on Monday, May 25th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $8.11.
BDSI opened at $4.07 on Friday. The firm has a 50-day simple moving average of $4.47 and a two-hundred day simple moving average of $4.67. BioDelivery Sciences International has a 52 week low of $2.85 and a 52 week high of $7.21. The company has a market capitalization of $424.72 million, a PE ratio of -45.22 and a beta of 0.75. The company has a quick ratio of 1.94, a current ratio of 2.19 and a debt-to-equity ratio of 0.77.
Individual investors are making an absolute killing on gold stocks. Here’s an under-the-radar Canadian gold company that has banked over 25 million oz of gold worth tens of $Billions for just $2/share. We’ve entered a gold bull market.
BioDelivery Sciences International (NASDAQ:BDSI) last released its quarterly earnings data on Thursday, May 7th. The specialty pharmaceutical company reported $0.05 EPS for the quarter, beating the consensus estimate of $0.01 by $0.04. BioDelivery Sciences International had a negative net margin of 5.01% and a positive return on equity of 23.61%. The business had revenue of $38.28 million during the quarter, compared to the consensus estimate of $33.19 million. As a group, sell-side analysts expect that BioDelivery Sciences International will post 0.2 earnings per share for the current year.
In other BioDelivery Sciences International news, insider James Vollins sold 21,666 shares of the firm’s stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $4.60, for a total value of $99,663.60. Following the completion of the sale, the insider now owns 21,666 shares of the company’s stock, valued at $99,663.60. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Mark A. Sirgo sold 100,000 shares of the firm’s stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $4.58, for a total transaction of $458,000.00. Following the completion of the sale, the director now directly owns 1,364,595 shares of the company’s stock, valued at approximately $6,249,845.10. The disclosure for this sale can be found here. In the last three months, insiders sold 221,666 shares of company stock valued at $1,064,664. 8.57% of the stock is owned by insiders.
Large investors have recently modified their holdings of the company. Canandaigua National Bank & Trust Co. purchased a new position in shares of BioDelivery Sciences International during the first quarter worth approximately $55,000. Ipswich Investment Management Co. Inc. purchased a new position in BioDelivery Sciences International during the first quarter valued at approximately $57,000. Credit Suisse AG increased its holdings in BioDelivery Sciences International by 368.2% during the fourth quarter. Credit Suisse AG now owns 100,940 shares of the specialty pharmaceutical company’s stock valued at $639,000 after buying an additional 79,381 shares during the period. Los Angeles Capital Management & Equity Research Inc. increased its holdings in BioDelivery Sciences International by 151.5% during the first quarter. Los Angeles Capital Management & Equity Research Inc. now owns 536,584 shares of the specialty pharmaceutical company’s stock valued at $2,034,000 after buying an additional 323,205 shares during the period. Finally, Wells Fargo & Company MN increased its holdings in BioDelivery Sciences International by 73.3% during the first quarter. Wells Fargo & Company MN now owns 300,305 shares of the specialty pharmaceutical company’s stock valued at $1,137,000 after buying an additional 127,021 shares during the period. 69.16% of the stock is currently owned by institutional investors and hedge funds.
About BioDelivery Sciences International
BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug-delivery technologies.
Read More: Why are analyst ratings important in trading stocks?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
8 Artificial Intelligence Stocks That Will Make You Feel Like a Smart Investor
In 2018, it was cannabis. In 2019, it was 5G. And yet before either of those trends, artificial intelligence (or AI) was growing relentlessly and undeniably.
Artificial intelligence stems from the simple fact that computers are getting smarter. And they are being designed to process information faster. The words “machine learning” are being used to summarize the creation of algorithms, freed from human programmers, which train themselves on massive data sets. Earlier this year, two separate artificial intelligence “machines” demonstrated the ability to “read” Wikipedia entries and answer questions better than humans did.
But AI is more than a parlor trick. Chances are at some point today, you’ve experienced a benefit of artificial intelligence. You may have gotten to this page because of an internet search. You may have asked Alexa or your Google Assistant to perform a command. You may have voice-activated your Roomba vacuum. You may have used an AI-powered GPS system to get to wherever you’re reading this.
In the future, you may be hailing an autonomous car. A virtual assistant will be able to place calls for you to make appointments. But instead of sounding like a robot, the assistant will sound human, with an understanding of context and nuance.
And those are just two applications. There will be more because the possibilities of artificial intelligence are expansive. But they can also be somewhat chilling. Many of the functions that are performed by humans today may be made obsolete by AI. But that’s a subject for another day.
Right now, you want to know how you can profit from this emerging trend.
You’ve come to the right place. In this special presentation, we will take a look at 8 stocks that can help you profit from the artificial intelligence trend.
View the “8 Artificial Intelligence Stocks That Will Make You Feel Like a Smart Investor”.
